Track market-moving stories before they get noisy

Key Takeaways ISRG is favored for its expanding robotic surgery ecosystem and stronger long-term growth outlook.Intuitive Surgical grew procedures, expanded its installed base and advanced da Vinci 5, SP and Ion.Abbott posted broad-based growth across devices, diagnostics, diabetes care and nutrition. Despite sharp declines in 2026, Intuitive Surgical (ISRG - Free Report) and Abbott Laboratories (ABT - Free Report) remain among the highest-quality names in MedTech. ISRG has declined 32.1% year to date, while ABT is down 20.1%, though both continue to execute well in their core businesses.

Intuitive Surgical’s growth is being fueled by the expanding adoption of its robotic surgery ecosystem, including da Vinci 5, SP and Ion platforms, while Abbott is benefiting from balanced momentum across cardiovascular devices, diagnostics, diabetes care and nutrition.

Looking ahead, both companies expect growth to continue through 2026, although Intuitive Surgical’s expanding robotic surgery franchise and innovation pipeline position it for stronger long-term upside.

YTD Price Chart ISRG vs ABT

Image Source: Zacks Investment Research

Case for ISRGIntuitive Surgical continues to widen its competitive moat by building a comprehensive robotic-assisted surgery ecosystem rather than relying on a single platform. During the second quarter, total procedures increased 16%, supported by 15% growth in da Vinci procedures and an impressive 36% increase in Ion procedures.

Adoption remained strong across da Vinci 5, single-port (SP) systems and Ion, while the company expanded its installed base to nearly 13,000 systems globally. Continued upgrades to da Vinci 5, broader adoption of XiR in ambulatory surgery centers and cost-sensitive international markets, and ongoing investments in AI-enabled workflow, simulation and telepresence reinforce management's long-term growth strategy.

Growth opportunities extend well beyond traditional robotic surgery. SP procedures surged 61%, Ion procedures surpassed 400,000 cumulatively, and management continues to invest in new disease areas such as gastrointestinal robotics, cardiac surgery and nipple-sparing mastectomy. Programs designed to reduce customer costs, including the upcoming EndoWrist extended-use initiative, should further expand adoption across outpatient procedures and international markets.

The company also faces several challenges, including slower U.S. elective procedure growth tied to changing patient coverage dynamics, competitive pressure in China, GLP-1-related weakness in bariatric surgery and higher R&D spending. Nevertheless, Intuitive Surgical continues to guide toward healthy procedure growth for 2026 while investing aggressively to extend its technology leadership.

ISRG’s Sales & EPS Growth Estimate

Image Source: Zacks Investment Research

Case for ABTAbbott's growth strategy is built on diversification across multiple healthcare markets rather than dependence on any single business. Medical Devices remained a key contributor in the second quarter, with 8.5% growth driven by electrophysiology, rhythm management, heart failure and continuous glucose monitoring. Management expects growth to accelerate further as Volt 2.0, TactiFlex Duo, Libre Duo, Amulet 360 and several cardiovascular products are commercialized over the coming year. Strong momentum in diagnostics, emerging-market pharmaceuticals and improving nutrition performance also support ABT’s balanced growth outlook.

Abbott's broad portfolio provides resilience, but it also means growth is spread across numerous franchises rather than being driven by a single transformational platform. While continuous glucose monitoring remains a significant long-term opportunity, management acknowledged that reimbursement expansion timing remains difficult to predict.

Cancer diagnostics, core laboratory testing and electrophysiology are expected to drive second-half acceleration, while nutrition continues recovering steadily. Risks include declining respiratory testing volumes, reimbursement uncertainties for diabetes products and the need to execute multiple product launches successfully to sustain projected acceleration. Overall, Abbott's diversified model provides stability but offers a less concentrated growth story than Intuitive Surgical's robotics franchise.

ABT’s Sales & EPS Growth Estimate

Image Source: Zacks Investment Research

Valuation ComparisonDespite a steep fall in its valuation since the beginning of 2025, ISRG trades at a premium, supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 30.55, above the industry average of 24.41, and carries a Value Score of D.

ISRG’s P/E F12M Chart

Image Source: Zacks Investment Research

ABT offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 17.33X, slightly above the industry average of 16.02X. ABT carries a Value Score of C.

ABT’s P/E F12M Chart

Image Source: Zacks Investment Research

ConclusionBoth companies possess durable competitive advantages and robust innovation pipelines. Abbott offers investors diversified exposure across diagnostics, cardiovascular devices, diabetes care and nutrition, helping reduce reliance on any single market. Intuitive Surgical stands out for its leadership in robotic-assisted surgery, expanding clinical indications, accelerating adoption of da Vinci 5, SP and Ion, and sustained investment in next-generation technologies. Although ISRG trades at a premium valuation, its stronger innovation pipeline, faster-growing robotic ecosystem and Zacks Rank #2 (Buy) make it a more compelling long-term MedTech investment than Abbott, which carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Posted by Defense World Staff on Jul 23rd, 2026

ABN Amro Investment Solutions increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 10.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,222 shares of the healthcare product maker’s stock after purchasing an additional 9,071 shares during the quarter. ABN Amro Investment Solutions’ holdings in Abbott Laboratories were worth $9,468,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank raised its holdings in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In ABT has been the subject of several research reports. The Goldman Sachs Group cut their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Barclays dropped their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Jefferies Financial Group cut their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Argus lowered their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Get Our Latest Report on Abbott Laboratories

Abbott Laboratories Price Performance NYSE:ABT opened at $100.69 on Thursday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a market cap of $175.38 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.93 and a beta of 0.61. The company’s 50-day moving average is $90.92 and its two-hundred day moving average is $101.48. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.51 EPS for the current year.

Abbott Laboratories Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Insider Activity In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEABN Amro Investment Solutions Sells 41,096 Shares of Ingersoll Rand Inc. $IR

NEXT HEADLINE »ABN Amro Investment Solutions Boosts Stake in International Business Machines Corporation $IBM

Abbott (ABT - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this maker of infant formula, medical devices and drugs have returned +15.8% over the past month versus the Zacks S&P 500 composite's -0.6% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 4.4% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Abbott is expected to post earnings of $1.42 per share for the current quarter, representing a year-over-year change of +9.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.3%.

The consensus earnings estimate of $5.51 for the current fiscal year indicates a year-over-year change of +7%. This estimate has changed +0.6% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $6.06 indicates a change of +10% from what Abbott is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Abbott, the consensus sales estimate of $12.98 billion for the current quarter points to a year-over-year change of +14.1%. The $50.28 billion and $54.6 billion estimates for the current and next fiscal years indicate changes of +13.4% and +8.6%, respectively.

Last Reported Results and Surprise HistoryAbbott reported revenues of $12.59 billion in the last reported quarter, representing a year-over-year change of +13%. EPS of $1.31 for the same period compares with $1.26 a year ago.

Compared to the Zacks Consensus Estimate of $12.48 billion, the reported revenues represent a surprise of +0.91%. The EPS surprise was +2.34%.

Over the last four quarters, Abbott surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 36.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 206,708 shares of the healthcare product maker’s stock after selling 118,500 shares during the quarter. Andra AP fonden’s holdings in Abbott Laboratories were worth $21,223,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the fourth quarter worth approximately $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the fourth quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets ABT has been the subject of several recent analyst reports. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Piper Sandler reissued an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.61.

View Our Latest Stock Report on ABT

Abbott Laboratories Trading Up 1.0% NYSE:ABT opened at $101.72 on Tuesday. The stock has a market cap of $177.18 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 1.73 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average price is $90.28 and its 200-day moving average price is $101.84. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is 81.55%.

Insider Transactions at Abbott Laboratories In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAssetmark Inc. Has $9.79 Million Stock Position in Spotify Technology $SPOT

NEXT HEADLINE »Baader Bank Aktiengesellschaft Trims Stock Holdings in Walmart Inc. $WMT

Posted by Defense World Staff on Jul 19th, 2026

Allspring Global Investments Holdings LLC raised its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 11.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 468,676 shares of the healthcare product maker’s stock after acquiring an additional 50,017 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Abbott Laboratories were worth $47,983,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. One Day In July LLC boosted its holdings in Abbott Laboratories by 3.6% in the first quarter. One Day In July LLC now owns 3,669 shares of the healthcare product maker’s stock worth $377,000 after purchasing an additional 127 shares during the last quarter. Independent Financial Group LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter worth $1,545,000. Frazier Financial Advisors LLC boosted its stake in shares of Abbott Laboratories by 7.8% in the 1st quarter. Frazier Financial Advisors LLC now owns 28,864 shares of the healthcare product maker’s stock worth $2,964,000 after buying an additional 2,089 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of Abbott Laboratories by 2.5% in the first quarter. D.A. Davidson & CO. now owns 186,786 shares of the healthcare product maker’s stock worth $19,177,000 after acquiring an additional 4,553 shares during the period. Finally, Beaumont Financial Advisors LLC increased its position in Abbott Laboratories by 193.8% during the first quarter. Beaumont Financial Advisors LLC now owns 69,183 shares of the healthcare product maker’s stock valued at $7,103,000 after acquiring an additional 45,634 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance NYSE:ABT opened at $100.71 on Friday. The business’s 50-day simple moving average is $89.89 and its two-hundred day simple moving average is $102.17. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market cap of $175.41 billion, a PE ratio of 32.59, a P/E/G ratio of 1.73 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results Insider Activity In related news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In Several equities research analysts have recently commented on ABT shares. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, April 22nd. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Oppenheimer decreased their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.61.

View Our Latest Report on Abbott Laboratories

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Recommended Stories Five stocks we like better than Abbott Laboratories Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAMG National Trust Bank Grows Position in JPMorgan Chase & Co. $JPM

NEXT HEADLINE »Concordia Financial Group (OTCMKTS:CCRDF) Director Purchases $1,003,436.10 in Stock

Posted by Defense World Staff on Jul 19th, 2026

Assetmark Inc. grew its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 8.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 202,552 shares of the healthcare product maker’s stock after purchasing an additional 16,506 shares during the period. Assetmark Inc.’s holdings in Abbott Laboratories were worth $20,796,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In ABT has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

View Our Latest Stock Report on ABT

Abbott Laboratories Trading Up 1.9% Abbott Laboratories stock opened at $100.71 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The business’s fifty day moving average is $89.89 and its 200 day moving average is $102.17. The stock has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Key Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results Insider Activity at Abbott Laboratories In other news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGilead Sciences, Inc. $GILD Shares Sold by Allspring Global Investments Holdings LLC

15.96K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted by _ _xnake on Jul 17th, 2026

Abbott Laboratories (NYSE:ABT – Get Free Report) shares gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $89.27, but opened at $95.29. Abbott Laboratories shares last traded at $100.4150, with a volume of 6,088,884 shares changing hands.

The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the company posted $1.26 EPS. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS.

Abbott Laboratories Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Key Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 expectations with adjusted EPS of $1.31 versus $1.28 expected, showing better-than-expected profitability. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60, above its prior range, signaling confidence in earnings momentum. Abbott raises 2026 profit forecast on heart device strength Positive Sentiment: Revenue grew 13% year over year, supported by strong demand in medical devices, diagnostics, and emerging markets, which points to broad-based operating strength. Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Positive Sentiment: Heart-device demand and diagnostics growth, including a surge in sales tied to that segment, improved investor sentiment around Abbott’s longer-term growth profile. Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market Neutral Sentiment: Abbott’s profit fell sharply from a year ago on a GAAP basis, but the decline was offset by stronger sales and guidance, making this more of a quality-over-headline-results story. Abbott Laboratories Sales Rise on Diagnostics Growth Negative Sentiment: Broader market and tech sell-off headlines may have slightly tempered enthusiasm, but they were not the main driver of ABT’s move. Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off Analyst Ratings Changes Several equities analysts have recently commented on the company. Leerink Partners reduced their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Evercore cut their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Benchmark decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $117.61.

Get Our Latest Analysis on ABT

Insider Transactions at Abbott Laboratories In related news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows Several hedge funds have recently made changes to their positions in ABT. American National Bank of Texas boosted its position in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after buying an additional 79 shares during the period. Nia Impact Advisors LLC grew its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the last quarter. Park Place Capital Corp increased its position in shares of Abbott Laboratories by 11.0% in the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after acquiring an additional 81 shares during the period. Lantern Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 1.7% during the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after acquiring an additional 84 shares during the last quarter. Finally, Clayton Financial Group LLC raised its stake in shares of Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after acquiring an additional 84 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 10.7% The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $172.11 billion, a PE ratio of 27.68, a price-to-earnings-growth ratio of 1.54 and a beta of 0.61. The stock’s fifty day moving average price is $89.56 and its two-hundred day moving average price is $102.18.

Abbott Laboratories Company Profile (Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEJames Hardie Industries PLC. (NYSE:JHX) Receives Average Rating of “Moderate Buy” from Brokerages

NEXT HEADLINE »Clean Harbors (NYSE:CLH) and China Everbright Environment Group�� (OTCMKTS:CHFFF) Critical Survey

Key Takeaways Abbott raised 2026 adjusted EPS guidance after Q2 earnings and revenues topped expectations.Nutrition, electrophysiology, Core Lab and Cancer Diagnostics should drive 80% of the lift.Libre reimbursement, new device launches and stronger diagnostics demand support the second-half setup. Abbott Laboratories (ABT - Free Report) used its second-quarter earnings call to press a forward message rather than dwell on the quarter itself. Management raised adjusted earnings guidance and said momentum is building across several businesses that should drive a faster back half.

The company’s tone was notably confident in both prepared remarks and Q&A, with executives pointing to improving nutrition trends, new electrophysiology launches, steadier diagnostics demand and a larger reimbursement runway in diabetes care.

ABT Raises 2026 Earnings ViewAbbott reported quarterly adjusted earnings of $1.31 per share, topping the Zacks Consensus Estimate of $1.28. Second-quarter revenues came in at $12.59 billion, which also beat the consensus mark of $12.48 billion. Comparable sales rose 4.8%, while adjusted gross margin expanded 100 basis points to 58%.

Chief executive officer Robert Ford said the quarter marked an acceleration from the prior two periods and gave management enough confidence to lift its full-year adjusted EPS range to $5.45-$5.60 from $5.38-$5.58. Abbott reaffirmed comparable sales growth guidance of 6.5% to 7.5%.

Chief financial officer Philip Boudreau added that foreign exchange was slightly better than expected in the quarter and said Abbott sees third-quarter adjusted EPS of $1.38 to $1.46.

Abbott Maps Out Four Growth DriversFord said about 80% of the expected second-half lift should come from four businesses: Nutrition, Electrophysiology, Core Laboratory and Cancer Diagnostics. He described each as entering the back half with momentum and clearer visibility into demand drivers.

Nutrition was one of the more important tone shifts on the call. Management said the business is tracking slightly ahead of plan, with international pediatric nutrition back to positive growth and U.S. pediatric trends now reflecting the full benefit of recent WIC contract wins.

On the adult side, Ford said Ensure consumption in the United States has improved sharply after pricing actions taken late last year. He also highlighted product refreshes and upcoming launches, including higher-protein, lower-sugar offerings and a new infant formula.

ABT Pushes for EP Share GainsMedical devices remained a key source of confidence. Ford said Abbott expects its electrophysiology franchise to begin outperforming the market in the second half as Volt 2.0 moves from limited to full U.S. release and TactiFlex Duo expands internationally.

The CEO said physician feedback on Volt has been strong, particularly around mapping integration and workflow. In Europe, EP sales grew more than 20%, reinforcing management’s view that the product cycle is gaining traction.

Q&A also showed where Abbott still has work to do. Ford said Structural Heart should return to mid- to high-single-digit growth by year-end, but acknowledged the U.S. mitral business needs better commercial execution even as international structural heart trends remain strong.

Abbott Waits on the Next Libre CatalystDiabetes care produced another large quarter, with continuous glucose monitoring sales topping $2 billion and growing 9.5% on a comparable basis. Management did not dismiss concerns about a slower growth rate, but framed the issue as a pause between reimbursement catalysts.

Ford said Abbott remains highly bullish on CGM adoption, arguing the addressable population is far larger than the current installed base. He pointed to active reimbursement discussions in roughly a dozen countries and said those decisions, when they arrive, can meaningfully reaccelerate growth.

The most closely watched catalyst remains expanded U.S. coverage for non-insulin type 2 users. Ford said that the opportunity could unlock about 10 million Medicare beneficiaries, while Abbott is also preparing to roll out Libre Duo internationally and considering a fifth manufacturing facility.

ABT Builds Around Cancer and Core LabDiagnostics commentary also carried a stronger forward tilt than the headline growth rate implied. Core Lab demand stayed firm, with U.S. growth of 7.5%, and Ford said hospital-based testing volumes remain healthy despite investor concerns about broader procedure softness.

Cancer Diagnostics added another important growth lever. Abbott said sales in that business grew 13.3% on a comparable basis, supported by mid-teens Cologuard growth, repeat screening, international expansion and contributions from precision oncology.

A key Q&A exchange centered on the Exact Sciences acquisition. Ford said integration is going well, reaffirmed a mid-teens growth view for 2026, and expressed confidence that care-gap programs and the shift to Cologuard Plus will support a stronger second half.

Abbott Carries a More Assertive ToneBeyond the specific businesses, the broader message was that January’s short-term issues are being worked through faster than expected. Ford said gross margin expansion is proving sustainable and added that cash generation should come in ahead of the company’s January outlook.

He also used the call to underline pipeline depth, citing recent milestones for Amulet 360, Libre Duo, Coronary IVL and several trial starts planned for the fourth quarter. That framing supported his view that Abbott can sustain about 7% top-line growth over time.

Zacks Signals Still Point to a Neutral SetupABT currently carries a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of C, Momentum Score of F and VGM Score of C. In Zacks terms, the Hold rank points to a more balanced near-term earnings revision picture than a clear bullish or bearish signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores add nuance. The stronger value profile stands out more than growth or momentum at the moment, while the middling VGM Score suggests the stock does not currently screen as one of the stronger all-around setups within the Zacks framework. That ranking can still change as estimate revisions adjust after the quarter.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Considering buying ABT stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

16.7.2026 22:00

Negativní sentiment se před koncem obchodní seance ještě více prohloubil. Může za to silný pokles technologického giganta Google, u kterého přišla zpráva, že je v několikaměsíčním zpoždění s vydáním nové vlajkové AI verze Geminy Pro 3.5. V prostředí velké konkurence to může mít neblahý efekt ztráty poptávky. Akcie Alphabet končí silnou ztrátou –4,43 %.

Nevalný výsledek zažil i čipový sektor, kde velkou váhu poklesu má na svědomí Micron -5,65 % či AMD -5,33 %.

Oproti tomu se dařilo defenzivním sektorům spotřebního zboží či služeb. McDonald přidal slušných +3,04 %, PepsiCo též +2,97 % a například kartová asociace Mastercard +3,04 %.

Ropa WTI stále mírně ztrácela -0,75 %. Negativní vývoj na burze tedy dnes nebyl ovlivněn negativní geopolitickou situací.

Index Dow Jones -0,2 % na 52553,62 b.
S&P 500 -0,51 % na 7533,89 b.
Nasdaq Composite -1,47 % na 25881,95 b.

Index S&P 500 -0,51 % na 7533,89 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Nezbytná spotřeba +2,9 % Komunikační služby -2,8 % Zdravotní péče +2,2 % Informační technologie -1,8 % Reality +2,1 % Zbytná spotřeba -0,3 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Abbott Laboratories (ABT) +11 % Sandisk Corp (SNDK) -13 % JB Hunt Transport Services (JBHT) +8,0 % Seagate Technology Holdings (STX) -10,0 % Fedex Freight Holding (FDXF) +7,5 % Corning (GLW) -9,2 % Erie Indemnity (ERIE) +7,5 % Western Digital Corp (WDC) -9,2 % Dexcom (DXCM) +7,2 % Marvell Technology (MRVL) -8,7 %
Jan Pazourek, Fio banka, a.s.

Key Takeaways Abbott beat Q2 earnings and revenue estimates as Medical Devices led comparable sales growth.ABT raised 2026 adjusted EPS guidance and reaffirmed 6.5%-7.5% comparable sales growth.ABT's Diagnostics gained from the Exact Sciences acquisition as Cancer Diagnostics grew in double digits. Abbott (ABT - Free Report) reported second-quarter 2026 adjusted earnings of $1.31 per share, up 4.0% year over year. The figure beat the Zacks Consensus Estimate by 2.34%.

Sales increased 13.0% year over year to $12.59 billion and surpassed the consensus mark by 0.91%. Comparable sales rose 4.8%, led by Medical Devices, while Cancer Diagnostics delivered double-digit growth.

Following the earnings announcement, ABT stock rose 3.2% in pre-market trading today.

ABT's Medical Devices Sustain MomentumMedical Devices sales increased 9.0% year over year on a reported basis to $5.85 billion. Comparable sales rose 8.4%, reflecting broad-based demand across several cardiovascular and diabetes-care businesses.

Electrophysiology sales climbed 13.4% on a comparable basis, while Rhythm Management and Heart Failure advanced 9.5% and 8.7%, respectively. Diabetes Care sales grew 9.0%, supported by a 9.5% increase in continuous glucose monitor sales. Vascular sales rose 5.1%, while Structural Heart improved 5.7%.

Abbott's Diagnostics Get Acquisition LiftDiagnostics sales surged 42.3% on a reported basis to $3.09 billion, reflecting the March 2026 acquisition of Exact Sciences. On a comparable basis, segment sales increased 2.9%.

Cancer Diagnostics sales totaled $919 million and grew 13.3% on a comparable basis. Performance benefited from mid-teens Cologuard growth and contributions from precision oncology and international operations. Core Laboratory Diagnostics sales rose 3.2%, driven by strength in the United States and Latin America.

Rapid and Molecular Diagnostics sales declined 8.0% on a comparable basis. The decrease reflected lower respiratory virus testing revenues compared with the prior-year period.

ABT's Nutrition Pressure PersistsNutrition sales declined 3.1% year over year on a reported basis to $2.14 billion. Comparable sales fell 3.6%, reflecting lower volumes and the impact of strategic pricing actions implemented in the fourth quarter of 2025.

Pediatric Nutrition sales decreased 3.1% on a comparable basis, while Adult Nutrition fell 4.0%. U.S. Nutrition remained particularly weak, with sales down 9.0%. However, total Nutrition revenues improved by $127 million sequentially from the first quarter, supported by pricing initiatives and new product launches.

Abbott's Pharma Growth Stays BroadEstablished Pharmaceutical sales increased 8.4% on a reported basis to $1.50 billion. Comparable growth was 8.7%, extending the segment’s steady expansion across international markets.

Key Emerging Markets sales rose 10.7% on a comparable basis. Double-digit growth in several Latin American and Asia-Pacific countries supported the performance. Sales in other markets increased 2.1%.

Q2 Margin Details of AbbottIn the second quarter, adjusted gross profit rose 15.1% year over year to $7.31 billion. The adjusted gross margin expanded 107 basis points (bps) to 58.0%.

Adjusted selling, general and administrative expenses increased 16.4% year over year to $3.60 billion. Adjusted research and development expenses grew 23.0% to $867 million. The company reported an adjusted operating profit of $2.84 billion, up 11.4% year over year. The adjusted operating margin contracted 32 bps to 22.6%.

ABT’s 2026 & Q3 Financial GuidanceAbbott raised its full-year 2026 adjusted earnings guidance to a range of $5.45-$5.60 per share. The prior outlook called for adjusted earnings of $5.38-$5.58 per share. The Zacks Consensus Estimate for the same currently stands at $5.48.

The company reaffirmed its full-year comparable sales growth forecast of 6.5-7.5%.

For the third quarter, management expects adjusted earnings of $1.38-$1.46 per share. The Zacks Consensus Estimate for the same is projected at $1.42.

Our TakeAbbott exited the second quarter of 2026 with earnings and revenues beating respective estimates. Within Diagnostics, Core Laboratory results benefited from strong growth in the United States and Latin America. Cancer Diagnostics gained from increasing adoption of Cologuard among new and repeat users, driving Cancer Diagnostics results. Expansion of the adjusted gross margin in the quarter is also encouraging. Meanwhile, lower year-over-year sales volumes and the effect of strategic pricing actions weighed on Nutrition results.

Abbott also highlighted several pipeline developments. The company completed enrollment in its TECTONIC U.S. pivotal trial for coronary intravascular lithotripsy and submitted its Amulet 360 left atrial appendage device to the FDA. It also secured CE Mark approval for Libre Duo, a wearable sensor that monitors glucose and ketone levels.

ABT’s Zacks Rank & Key PicksAbbott currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are CVS Health (CVS - Free Report) , Charles River Laboratories International (CRL - Free Report) and Phibro Animal Health (PAHC - Free Report) .

CVS Health, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.57, which surpassed the Zacks Consensus Estimate by 16.38%. Revenues of $100.43 billion beat the Zacks Consensus Estimate by 6.41%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

CVS has an earnings yield of 7% compared to the industry’s 4.2% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.79%.

Charles River Laboratories,carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.06, beating the Zacks Consensus Estimate by 5.1%. Revenues of $995.8 million topped the Zacks Consensus Estimate by 2.5%.

CRL has an earnings yield of 4.8% compared to the industry’s 4.3% yield. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.31%.

Phibro Animal Health,carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2026 adjusted EPS of 64 cents, surpassing the Zacks Consensus Estimate by 5.92%. Revenues of $383.5 million topped the Zacks Consensus Estimate by 6.26%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.25%.

Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.

Abbott Laboratories Today

ABT

Abbott Laboratories

$99.03 +9.76 (+10.93%)

As of 02:37 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$81.97▼

$137.49Dividend Yield2.54%

P/E Ratio27.70

Price Target$117.61

Looking forward, profitability metrics have improved, leading to improved guidance, strengthened market sentiment, and a robust rebound in the share price.

Get Abbott Laboratories alerts:

The share price rebound is an operative factor in the second half of 2026. Abbott’s market was overly depressed, given its historical value and capacity for capital returns, signaling a buying opportunity for investors.

The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting a full reversal is in play. The market completely misjudged the Exact Sciences deal, focusing too intently on near-term margin pressure and execution risk, rather than the long-term commercial impact on revenue, margins, and earnings.

Abbott Laboratories Q2 Report a Balm for Frayed Investor NervesAbbott Laboratories' Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, aided by an 8.4% increase in Established Pharmaceuticals and a 7.9% increase in Medical Devices. Nutrition, among the smaller segments, declined by 3.1%. Regionally, strengths were seen domestically and abroad.

Margin news was the catalyzing factor. The company’s margins contracted but less than expected, leaving gross margin, operating and net income above analysts' forecasts. The critical takeaway is that $1.31 in adjusted earnings per share (EPS) outperformed by 235 basis points and is sufficient to sustain financial health while reinvesting and returning capital to shareholders.

Guidance is another catalyzing factor for back-half trading. The company maintained its forecast for organic revenue growth but improved the outlook for earnings, lifting the midpoint and narrowing the range for full-year results. With momentum building and results forecasted to accelerate in the back half, the guidance is likely to be cautious, setting the stage for additional catalysts by year’s end.

Abbott’s Capital Return Outlook ImprovesAbbott’s capital return was never in any real danger, but the threat of margin compression and cash flow impairment was sufficient to weigh on sentiment. The takeaway from the Q2 release, however, is that concerns are misplaced. Capital returns will continue to flow, including the dividend and share buybacks, and buybacks may accelerate.

As it stands, Abbott is a Dividend King with nearly 55 consecutive increases to its credit, a manageable 70% payout ratio, and buybacks to offset the impact of annual increases and build shareholder leverage. The dividend yield is more than attractive, as of mid-July, at a historical high of approximately 2.8%, and Q2 buybacks reduced the count by 0.45%.

Analysts and Institutional Trends Reveal Optimistic Support for ABT SharesAnalysts' trends reflect the dividend safety and deep value opportunity presented this year. While price targets have moderated, the market overreacted and moved below the low end of the target range. Price targets suggest a floor near $90, with potential for substantial upside at the consensus. Valuation metrics suggest the upside will run into the triple digits over time.

The likely outcome is that analysts' price targets begin to firm, increasing conviction in the consensus and potential for a full stock price recovery. Until then, institutional activity suggests this group limits risk in 2026, owning more than 75% of the shares and buying on balance. Buying is broad-based, including funds, mutual funds, public retirement accounts, and private wealth managers.

Abbott’s risks center on legacy issues related to its baby formula business, competition in the MedTech sector, and the integration of Exact Sciences. Integration risks now appear limited, given the Q2 release and guidance update, leaving competition and legacy issues as the primary hurdles. Competition is being mitigated through pipeline investment, with numerous positive developments reported this quarter. Legacy issues relate to baby formula manufacturing processes, regulatory scrutiny, and the unresolved legal issues they bring.

This year’s catalysts include the successful integration of Exact Sciences, the revenue and margin boost from Cologuard, and the expansion of Medtech wearables. Libre Duo, the world’s first dual glucose/keytone monitoring system, received the EU’s CE Mark, enabling its sales throughout the region, while pipeline news includes advances in two critical cardiovascular devices. What the market gets wrong is that ABT isn’t just a legacy healthcare company and bond proxy but an innovative med-tech company expanding margins while investing in growth.

Should You Invest $1,000 in Abbott Laboratories Right Now?Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetAbbott Laboratories NYSE: ABT reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters.

The company reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5% and raised its adjusted EPS guidance range to $5.45 to $5.60. Chief Financial Officer Phil Boudreau said Abbott expects third-quarter adjusted EPS of $1.38 to $1.46.

Get Abbott Laboratories alerts:

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Ford said Abbott entered the second half of the year with “momentum building across the portfolio” and “clear line of sight” to the drivers behind expected sales growth acceleration. He said the company’s focus on gross margin expansion supported the higher earnings outlook.

Margins Improve as Sales Growth Accelerates Boudreau said second-quarter adjusted gross margin was 58.0% of sales, up 100 basis points from the prior year. He attributed the improvement to favorable business mix within Abbott’s legacy portfolio, the addition of Exact Sciences, operational improvements and disciplined execution of margin expansion initiatives.

Abbott Stock Crash: Rebound Could Be Coming FastAdjusted research and development expense was 6.9% of sales, while adjusted selling, general and administrative expense was 28.6% of sales. Foreign exchange had a favorable 0.8% year-over-year impact on second-quarter sales, slightly better than Abbott expected in April. Based on current rates, Boudreau said the company expects foreign exchange to have a positive impact of about 1% on full-year sales, including an expected negative impact of about 1% in the third quarter.

Diagnostics and Nutrition Show Mixed Trends In diagnostics, Ford said Abbott’s core laboratory business reflected strong demand for testing, which he described as a useful indicator of broader healthcare activity. U.S. core laboratory sales grew 7.5%, and Ford said the company continued to post strong performance in Latin America. During the question-and-answer session, he said hospital lab testing within Abbott’s U.S. core lab business was up 13% in the quarter.

Rapid and molecular diagnostics sales declined 8%, driven by an expected drop in respiratory virus testing following a weaker-than-normal season that ended during the quarter.

Cancer diagnostics sales grew 13%, supported by mid-teens growth in Cologuard, contributions from precision oncology and international growth. Ford said Abbott continues to expect cancer diagnostics growth in the second half to exceed first-half growth, helped by care gap programs, recently launched tests and international adoption. He also noted that the American Cancer Society updated its colorectal cancer screening guidelines in May, reaffirming Cologuard and Cologuard Plus as preferred screening options.

Nutrition sales came in slightly ahead of Abbott’s expectations for the second straight quarter, according to Ford. Sales increased sequentially by $125 million, supported by improving trends in both pediatric and adult nutrition. International pediatric nutrition returned to positive growth, rising 6.5% in the quarter. In the U.S. pediatric business, Ford said Abbott exited the quarter with the full benefit of recent WIC contract wins in its run rate and is now the market leader in both WIC and non-WIC segments.

In adult nutrition, Ford said the company continued to see positive volume trends after price actions taken late last year. U.S. retail consumption of Ensure rose by double digits compared with levels exiting last year. Abbott is also seeing contributions from new versions of Ensure featuring higher protein, lower sugar and updated labeling and packaging.

Medical Devices Growth Led by EP, Rhythm Management and Diabetes Care Medical devices sales grew 8.5%, with Abbott’s cardiovascular device portfolio also up 8.5%. Ford said growth was led by low-teens growth in electrophysiology and high-single-digit growth in rhythm management and heart failure.

In electrophysiology, Ford said the second quarter marked the beginning of an acceleration in the business. Abbott launched its next-generation Volt pulsed field ablation catheter, commonly called Volt 2.0, in the U.S. in May and expects to move from limited market release to full market release in the third quarter. Internationally, the rollout of Volt and TactiFlex Duo is gaining traction, with growth of more than 20% in Europe.

Rhythm management sales grew 9.5%, supported by expanded use of the AVEIR pacemaker across single- and dual-chamber segments and broader international adoption. Heart failure sales grew 9%, led by double-digit growth in the U.S. from Abbott’s heart assist devices.

In diabetes care, continuous glucose monitoring sales exceeded $2 billion and grew 9.5%. Abbott received CE mark in May for Libre Duo, which Ford described as the world’s first dual glucose-ketone wearable sensor. The company plans to begin the international rollout in the fall and bring the product to the U.S. after FDA approval.

Pipeline Updates Include New Launches and Clinical Trials Ford highlighted several pipeline milestones, including completion of patient enrollment in the TECTONIC coronary intravascular lithotripsy pivotal trial and completion of Abbott’s FDA submission for approval of its new Amulet 360 left atrial appendage device.

He said Abbott expects to launch Amulet 360, Libre Duo, its coronary IVL product and TactiFlex Duo PFA catheter in the U.S. over the next 12 months. The company also remains on track to begin patient enrollment in the fourth quarter for several clinical trials, including studies for a balloon-expandable TAVR valve, a leadless conduction system pacing device using the AVEIR platform, a mitral replacement valve developed after Abbott’s acquisition of Cephea Valve Technologies, a peripheral IVL device developed after the acquisition of CSI and a wearable continuous lactate monitoring sensor intended to reduce sepsis risk after hospital discharge.

Management Addresses Demand, CGM Reimbursement and 2027 Setup During the call’s Q&A session, Ford said Abbott is not seeing signs of weakening procedure volumes in its businesses, despite investor concerns tied to hospital-sector preannouncements and possible Medicaid disenrollment. He said Medicare, not Medicaid, is the larger payer for many medical device procedures, including more than two-thirds of Abbott’s U.S. cardiovascular business. He also said demand for high-acuity, life-saving products is “very inelastic.”

Ford said 80% of Abbott’s expected second-half growth acceleration is expected to come from four areas: nutrition, electrophysiology, core laboratory and cancer diagnostics.

On continuous glucose monitoring, Ford said Abbott remains bullish on the market, estimating that 75 million to 80 million people globally could realistically use CGM, compared with about 15 million today. He said reimbursement expansion is the most immediate driver of adoption, and Abbott is in discussions with about a dozen countries on introducing or expanding coverage. In the U.S., he said broader type 2 diabetes coverage could unlock about 10 million Medicare beneficiaries and accelerate commercial insurance coverage, though he did not provide a specific timing forecast.

Looking beyond 2026, Ford declined to provide specific 2027 guidance but said Abbott continues to target high-single-digit top-line growth and double-digit earnings growth. He described 7% sales growth as a sustainable target for the company, supported by its mix of nutrition, diagnostics, established pharmaceuticals and medical technology businesses.

About Abbott Laboratories NYSE: ABTAbbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Abbott Laboratories Right Now?Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

16.7.2026 16:26, ABT

Americká zdravotnická společnost Abbott Laboratories zveřejnila své výsledky hospodaření za druhý kvartál roku 2026. Firma překonala odhady Wall Street jak na úrovni tržeb, tak očištěného zisku na akcii, a to díky zlepšené výkonnosti napříč většinou svých divizí. Vedení podniku zároveň zvýšilo výhled celoročního očištěného zisku na akcii.

Výsledky společnosti Abbott Laboratories (ABT) za 2Q 2026   2Q 2026 Konsensus 2Q 2026 2Q 2025 Tržby (mld. USD) 12,59 12,54 11,14 Čistý zisk (mld. USD) 0,93 -- 1,78 Očištěný zisk na akcii (EPS, USD/akcie) 1,31 1,28 1,26 Výsledky za 2Q Tržby společnosti ve druhém kvartále meziročně vzrostly o 13 % na 12,59 mld. USD při očekávání trhu 12,54 mld. USD. Porovnatelné tržby zaznamenaly meziroční růst o 4,8 %.

Nejvyšší podíl na tržbách tvoří prodej lékařských zařízení, který meziročně vzrostl o 9 % na 5,85 mld. USD při očekávání 5,82 mld. USD. Tržby z péče o diabetiky zde zaznamenaly meziroční růst o 10,5 % na 2,19 mld. USD při konsensu 2,17 mld. USD.

Tržby z diagnostiky meziročně vzrostly o 42,3 % na 3,09 mld. USD při odhadech 3,04 mld. USD, přičemž výrazný reportovaný růst odráží především konsolidaci akvizice Exact Sciences (na porovnatelné bázi divize rostla o 2,9 %).

Tržby z prodejů výživy zaznamenaly meziroční pokles o 3,1 % na 2,14 mld. USD při očekávání 2,12 mld. USD. Výsledky odrážejí nižší prodejní objemy a vliv cenových opatření zavedených ve čtvrtém kvartále loňského roku.

Tržby ze zavedených léčiv rostly 8,4% tempem na 1,50 mld. USD při projekcích 1,48 mld. USD.

Návrat kapitálu akcionářům Společnost během kvartálu vrátila akcionářům 2,1 mld. USD formou dividend a zpětných odkupů akcií. Představenstvo zároveň deklarovalo kvartální dividendu ve výši 0,63 USD na akcii.

Výhled na 3Q Společnost pro třetí kvartál roku 2026 očekává očištěný zisk na akcii ve výši 1,38 až 1,46 USD (odhad trhu: 1,42 USD).

Celoroční výhled Pro celý rok 2026 firma zvýšila prognózu očištěného zisku na akcii na 5,45 až 5,60 USD z původních 5,38 až 5,58 USD (očekávání: 5,48 USD). Společnost zároveň potvrdila výhled porovnatelného růstu tržeb o 6,5 až 7,5 %.

Komentář CEO „Naše výsledky za druhý kvartál odrážejí momentum, které budujeme,“ uvedl Robert B. Ford, předseda představenstva a generální ředitel společnosti. „Očekáváme, že toto momentum bude pokračovat a ve druhé polovině roku povede ke zrychlujícímu se růstu tržeb i zisku.“

Pohled analytiků Analytička Joanne Wuensch z Citi vnímá výsledky za 2Q jako mírně lepší, než se čekalo. Vzhledem k obavám ohledně objemů a konkurence, s nimiž trh do kvartálu vstupoval, by dle ní měla zveřejněná čísla rozptýlit část investorských obav, a to zejména v segmentu zdravotnické techniky.

Analytička Marie Thibault z BTIG hodnotí druhý kvartál jako lepší, než se trh obával s mírným překonáním odhadů tržeb, solidním překonáním očekávání na úrovni očištěného zisku na akcii, potvrzeným celoročním výhledem a výhledem na 3Q v souladu s konsensem. Pozitivně vnímá výrazné mezikvartální zlepšení tržeb divize výživy, které považuje za známku toho, že strategická cenová opatření zavedená ve čtvrtém kvartále zlepšují výsledky této kategorie. Zmínku vedení o momentu z 2Q a očekávaném zrychlení ve druhé polovině roku 2026 pak interpretuje jako signál stability v počtu podstupovaných zákroků, což označuje za jasné pozitivum.

Analytik Rick Wise ze Stifel uvedl, že Abbott doručil celkově výsledky v souladu s očekáváním a v některých ohledech lepší. Poznamenává, že výkonnost ve druhém kvartále odstartovala nezbytné zrychlování růstu, které je potřebné k dosažení celoročního výhledu.

Analytik Matt Henriksson z Bloomberg Intelligence míní, že vzhledem k nízkým očekáváním by měla zveřejněná čísla stačit ke zmírnění obav investorů, byť mohou přetrvávat otázky ohledně cesty zpět k udržitelnému dvoucifernému růstu.

Akcie Abbott Laboratories

Akcie Abbott Laboratories (ABT) připisují 12,5 % na 100,405 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 174,9 P/E 26,3 Vývoj za letošní rok (%) -19,9 Očekávané P/E 18,4 52týdenní minimum (USD) 82,0 Prům. cílová cena (USD) 116,3 52týdenní maximum (USD) 137,5 Dividendový výnos (%) 2,5 Zdroj: Abbott Laboratories, Bloomberg

Michal Bárta, Fio banka, a.s.

Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹ Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58 Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.

Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis. Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items. Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1. Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58. In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation. In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios. In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device. In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC. "Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."

SECOND-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

5,216

871

1,660

—

2,680

International

7,377

1,273

1,432

1,499

3,173

Total reported

12,593

2,144

3,092

1,499

5,853

% Change vs. 2Q25

U.S.

22.0

(9.0)

104.8

n/a

7.0

International

7.5

1.4

5.1

8.4

10.7

Total reported

13.0

(3.1)

42.3

8.4

9.0

Total reported excl. foreign exchange impact

12.2

(3.6)

41.3

8.7

7.9

Comparable sales growth

4.8

(3.6)

2.9

8.7

8.4

    U.S.

3.5

(9.0)

4.0

n/a

8.0

    International

5.8

0.6

1.6

8.7

8.7

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

9,490

1,715

2,565

—

5,203

International

14,267

2,446

2,707

2,925

6,189

Total reported

23,757

4,161

5,272

2,925

11,392

% Change vs. 1H25

U.S.

12.4

(10.3)

52.5

n/a

7.4

International

9.3

—

6.4

10.7

14.2

Total reported

10.5

(4.5)

24.7

10.7

11.0

Total reported excl. foreign exchange impact

8.2

(5.6)

22.4

8.9

8.0

Comparable sales growth

4.3

(5.6)

2.4

8.9

8.4

    U.S.

3.0

(10.3)

3.0

n/a

8.3

    International

5.3

(1.9)

1.6

8.9

8.5

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

871

525

346

International

1,273

500

773

Total reported

2,144

1,025

1,119

% Change vs. 2Q25

U.S.

(9.0)

(10.7)

(6.4)

International

1.4

7.3

(2.0)

Total reported

(3.1)

(2.7)

(3.4)

Total reported excl. foreign exchange impact

(3.6)

(3.1)

(4.0)

Comparable sales growth

(3.6)

(3.1)

(4.0)

    U.S.

(9.0)

(10.7)

(6.4)

    International

0.6

6.4

(2.8)

Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026. 

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)

Total

Pediatric

Adult

U.S.

1,715

1,036

679

International

2,446

942

1,504

Total reported

4,161

1,978

2,183

% Change vs. 1H25

U.S.

(10.3)

(11.9)

(7.8)

International

—

2.4

(1.5)

Total reported

(4.5)

(5.6)

(3.5)

Total reported excl. foreign exchange impact

(5.6)

(6.4)

(4.9)

Comparable sales growth

(5.6)

(6.4)

(4.9)

    U.S.

(10.3)

(11.9)

(7.8)

    International

(1.9)

0.7

(3.5)

Diagnostics*

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

1,660

377

890

393

International

1,432

1,041

29

362

Total reported

3,092

1,418

919

755

% Change vs. 2Q25

U.S.

104.8

7.5

n/a

(14.5)

International

5.1

3.4

n/a

2.0

Total reported

42.3

4.4

n/a

(7.3)

Total reported excl. foreign exchange impact

41.3

3.2

n/a

(8.0)

Comparable sales growth

2.9

3.2

13.3

(8.0)

    U.S.

4.0

7.5

13.3

(14.5)

    International

1.6

1.7

13.8

0.5

Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.

Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.

Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.

Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses. 

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

2,565

724

983

858

International

2,707

1,966

32

709

Total reported

5,272

2,690

1,015

1,567

% Change vs. 1H25

U.S.

52.5

6.0

n/a

(14.1)

International

6.4

6.1

n/a

2.4

Total reported

24.7

6.1

n/a

(7.4)

Total reported excl. foreign exchange impact

22.4

3.2

n/a

(8.8)

Comparable sales growth

2.4

3.2

13.3

(8.8)

    U.S.

3.0

6.0

13.2

(14.1)

    International

1.6

2.2

16.5

(1.1)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Established Pharmaceuticals

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,499

1,164

335

Total reported

1,499

1,164

335

% Change vs. 2Q25

U.S.

n/a

n/a

n/a

International

8.4

9.8

3.7

Total reported

8.4

9.8

3.7

Total reported excl. foreign exchange impact

8.7

10.7

2.1

Comparable sales growth

8.7

10.7

2.1

    U.S.

n/a

n/a

n/a

    International

8.7

10.7

2.1

Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. 

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

2,925

2,253

672

Total reported

2,925

2,253

672

% Change vs. 1H25

U.S.

n/a

n/a

n/a

International

10.7

11.3

8.6

Total reported

10.7

11.3

8.6

Total reported excl. foreign exchange impact

8.9

10.1

4.9

Comparable sales growth

8.9

10.1

4.9

    U.S.

n/a

n/a

n/a

    International

8.9

10.1

4.9

Medical Devices

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,680

377

420

313

294

225

189

862

International

3,173

366

441

88

509

372

71

1,326

Total reported

5,853

743

861

401

803

597

260

2,188

% Change vs. 2Q25

U.S.

7.0

10.7

15.9

10.9

3.9

(9.8)

(2.1)

8.6

International

10.7

10.0

12.3

3.0

7.5

12.1

14.7

11.7

Total reported

9.0

10.4

14.0

9.0

6.1

2.7

2.0

10.5

Total reported excl. foreign exchange impact

7.9

9.5

13.4

8.7

5.1

1.7

1.2

9.0

Comparable sales growth

8.4

9.5

13.4

8.7

5.1

5.7

1.2

9.0

    U.S.

8.0

10.7

15.9

10.9

3.9

(0.9)

(2.1)

8.6

    International

8.7

8.3

11.1

1.3

5.8

10.2

11.3

9.2

Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.

Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.

In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis. 

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

5,203

716

798

605

585

449

366

1,684

International

6,189

711

851

185

995

726

137

2,584

Total reported

11,392

1,427

1,649

790

1,580

1,175

503

4,268

% Change vs. 1H25

U.S.

7.4

11.1

14.8

11.1

6.2

(9.6)

(0.7)

9.2

International

14.2

15.9

15.7

13.5

8.7

18.1

20.4

14.0

Total reported

11.0

13.4

15.3

11.7

7.7

5.7

4.3

12.1

Total reported excl. foreign exchange impact

8.0

10.9

13.0

10.4

5.0

2.6

2.6

8.2

Comparable sales growth

8.4

10.9

13.0

10.4

5.0

6.2

2.6

8.2

    U.S.

8.3

11.1

14.8

11.1

6.2

(2.2)

(0.7)

9.2

    International

8.5

10.7

11.2

7.8

4.3

12.4

13.2

7.5

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.

Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 410th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Second Quarter Ended June 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

2Q26

2Q25

% Change

Net Sales

$12,593

$11,142

13.0

Cost of products sold, excluding amortization expense

5,325

4,854

9.7

Amortization of intangible assets

658

420

56.8

Research and development

892

725

22.9

Selling, general, and administrative

4,025

3,091

30.3

Total Operating Cost and Expenses

10,900

9,090

19.9

Operating Earnings

1,693

2,052

(17.5)

Interest expense, net

299

50

n/m

Net foreign exchange (gain) loss

4

(11)

n/m

Other (income) expense, net

(134)

(137)

(2.5)

Earnings before taxes

1,524

2,150

(29.1)

Taxes on Earnings

596

371

60.8

1)

Net Earnings

$928

$1,779

(47.8)

Net Earnings excluding Specified Items, as described below

$2,290

$2,213

3.5

2)

Diluted Earnings per Common Share

$0.53

$1.01

n/m

Diluted Earnings per Common Share, excluding Specified Items, as described below

$1.31

$1.26

4.0

2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

1,743

1,751

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Half Ended June 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

1H26

1H25

% Change

Net Sales

$23,757

$21,500

10.5

Cost of products sold, excluding amortization expense

10,215

9,322

9.6

Amortization of intangible assets

1,080

840

28.5

Research and development

1,659

1,441

15.1

Selling, general, and administrative

7,765

6,152

26.2

Total Operating Cost and Expenses

20,719

17,755

16.7

Operating Earnings

3,038

3,745

(18.9)

Interest expense, net

367

99

n/m

Net foreign exchange (gain) loss

(9)

(18)

n/m

Other (income) expense, net

(293)

(264)

10.6

Earnings before taxes

2,973

3,928

(24.3)

Taxes on earnings

968

824

17.5

1)

Net Earnings

$2,005

$3,104

n/m

Net Earnings excluding Specified Items, as described below

$4,312

$4,132

4.4

2)

Diluted Earnings per Common Share

$1.14

$1.77

n/m

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$2.46

$2.35

4.7

2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,745

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Second Quarter Ended June 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

2Q26

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      658

$     (658)

$        —

Gross Margin

6,610

697

7,307

R&D

892

(25)

867

SG&A

4,025

(428)

3,597

Other (income) expense, net

(134)

(27)

(161)

Earnings before taxes

1,524

1,177

2,701

Taxes on Earnings

596

(185)

411

Net Earnings

928

1,362

2,290

Diluted Earnings per Share

$     0.53

$      0.78

$      1.31

Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

2Q25

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      420

$     (420)

$        —

Gross Margin

5,868

478

6,346

R&D

725

(20)

705

SG&A

3,091

(1)

3,090

Other (income) expense, net

(137)

(1)

(138)

Earnings before taxes

2,150

500

2,650

Taxes on Earnings

371

66

437

Net Earnings

1,779

434

2,213

Diluted Earnings per Share

$      1.01

$      0.25

$      1.26

Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

First Half Ended June 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

1H26

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$    1,080

$   (1,080)

$        —

Gross Margin

12,462

1,129

13,591

R&D

1,659

(49)

1,610

SG&A

7,765

(901)

6,864

Other (income) expense, net

(293)

(34)

(327)

Earnings before taxes

2,973

2,113

5,086

Taxes on Earnings

968

(194)

774

Net Earnings

2,005

2,307

4,312

Diluted Earnings per Share

$      1.14

$      1.32

$     2.46

Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

1H25

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$      840

$     (840)

$        —

Gross Margin

11,338

926

12,264

R&D

1,441

(47)

1,394

SG&A

6,152

(11)

6,141

Other (income) expense, net

(264)

(36)

(300)

Earnings before taxes

3,928

1,020

4,948

Taxes on Earnings

824

(8)

816

Net Earnings

3,104

1,028

4,132

Diluted Earnings per Share

$      1.77

$      0.58

$     2.35

Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below: 

2Q26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    1,524

$      596

39.1 %

1)

Specified items

1,177

(185)

Excluding specified items

$    2,701

$       411

15.2 %

2Q25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,150

$       371

17.3 %

2)

Specified items

500

66

Excluding specified items

$    2,650

$      437

16.5 %

1)

2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

1H26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,973

$      968

32.5 %

3)

Specified items

2,113

(194)

Excluding specified items

$    5,086

$      774

15.2 %

1H25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    3,928

$      824

21.0 %

4)

Specified items

1,020

(8)

Excluding specified items

$   4,948

$      816

16.5 %

3)

2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Second Quarter Ended June 30, 2026 and 2025

($ in millions)

(unaudited)

2Q26

2Q25

% Change vs. 2Q25

Non-GAAP

Abbott
Reported

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

12,593

(86)

12,507

11,142

811

(22)

11,931

13.0

4.8

U.S.

5,216

—

5,216

4,276

786

(22)

5,040

22.0

3.5

Intl

7,377

(86)

7,291

6,866

25

—

6,891

7.5

5.8

Total Diagnostics

3,092

(22)

3,070

2,173

811

—

2,984

42.3

2.9

U.S.

1,660

—

1,660

811

786

—

1,597

104.8

4.0

Intl

1,432

(22)

1,410

1,362

25

—

1,387

5.1

1.6

Total Cancer Diagnostics

919

—

919

—

811

—

811

n/a

13.3

U.S.

890

—

890

—

786

—

786

n/a

13.3

Intl

29

—

29

—

25

—

25

n/a

13.8

Total Medical Devices

5,853

(57)

5,796

5,369

—

(22)

5,347

9.0

8.4

U.S.

2,680

—

2,680

2,503

—

(22)

2,481

7.0

8.0

Intl

3,173

(57)

3,116

2,866

—

—

2,866

10.7

8.7

Total Structural Heart*

597

(6)

591

581

—

(22)

559

2.7

5.7

U.S.

225

—

225

249

—

(22)

227

(9.8)

(0.9)

Intl

372

(6)

366

332

—

—

332

12.1

10.2

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

First Half Ended June 30, 2026 and 2025

($ in millions)

(unaudited)

1H26

1H25

% Change vs. 1H25

Non-GAAP

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

23,757

706

(8)

(500)

23,955

21,500

1,518

(46)

22,972

10.5

4.3

U.S.

9,490

681

(8)

—

10,163

8,444

1,470

(46)

9,868

12.4

3.0

Intl

14,267

25

—

(500)

13,792

13,056

48

—

13,104

9.3

5.3

Total Diagnostics

5,272

706

—

(98)

5,880

4,227

1,518

—

5,745

24.7

2.4

U.S.

2,565

681

—

—

3,246

1,682

1,470

—

3,152

52.5

3.0

Intl

2,707

25

—

(98)

2,634

2,545

48

—

2,593

6.4

1.6

Total Cancer Diagnostics

1,015

706

—

(1)

1,720

—

1,518

—

1,518

n/a

13.3

U.S.

983

681

—

—

1,664

—

1,470

—

1,470

n/a

13.2

Intl

32

25

—

(1)

56

—

48

—

48

n/a

16.5

Total Medical Devices

11,392

—

(8)

(306)

11,078

10,264

—

(46)

10,218

11.0

8.4

U.S.

5,203

—

(8)

—

5,195

4,842

—

(46)

4,796

7.4

8.3

Intl

6,189

—

—

(306)

5,883

5,422

—

—

5,422

14.2

8.5

Total Structural Heart*

1,175

—

(8)

(35)

1,132

1,112

—

(46)

1,066

5.7

6.2

U.S.

449

—

(8)

—

441

497

—

(46)

451

(9.6)

(2.2)

Intl

726

—

—

(35)

691

615

—

—

615

18.1

12.4

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           32

$               4

$         658

$            3

$         697

R&D

(10)

—

—

(15)

(25)

SG&A

(42)

(1)

—

(385)

(428)

Other (income) expense, net

1

(1)

—

(27)

(27)

Earnings before taxes

$           83

$               6

$         658

$         430

1,177

Taxes on Earnings (d)

(185)

Net Earnings

$        1,362

Diluted Earnings per Share

$        0.78

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)

Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or 
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$             1

$             55

$         420

$            2

$         478

R&D

—

(7)

—

(13)

(20)

SG&A

(3)

1

—

1

(1)

Other (income) expense, net

(1)

—

—

—

(1)

Earnings before taxes

$            5

$              61

$         420

$           14

500

Taxes on Earnings (d)

66

Net Earnings

$         434

Diluted Earnings per Share

$        0.25

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           34

$               11

$       1,080

$            4

$        1,129

R&D

(11)

(10)

—

(28)

(49)

SG&A

(486)

(34)

—

(381)

(901)

Other (income) expense, net

(1)

(3)

—

(30)

(34)

Earnings before taxes

$         532

$             58

$       1,080

$         443

2,113

Taxes on Earnings (d)

(194)

Net Earnings

$       2,307

Diluted Earnings per Share

$         1.32

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)

Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$             1

$              81

$         840

$            4

$         926

R&D

(1)

(23)

—

(23)

(47)

SG&A

(6)

(6)

—

1

(11)

Other (income) expense, net

(25)

—

—

(11)

(36)

Earnings before taxes

$           33

$             110

$         840

$           37

1,020

Taxes on Earnings (d)

(8)

Net Earnings

$       1,028

Diluted Earnings per Share

$        0.58

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

SOURCE Abbott

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Open Grid Scheduler / Grid Engine / Wikimedia Commons

The market still treats Abbott Laboratories (NYSE:ABT | ABT Price Prediction) like a bond proxy with a stethoscope: baby formula, branded generics, and a metronomic dividend. That framing looks increasingly stale, and the stock’s punishing drawdown has widened the gap between narrative and numbers.

Abbott is a card-carrying S&P 500 Dividend Aristocrat, riding a 54th consecutive year of dividend increases and a 410th consecutive quarterly payout of $0.63 per share. A beta of 0.607 reinforces the “sleep well at night” identity. That reputation is precisely why the transformation underneath it is being underpriced.

A New Growth Engine and a Pivot Hiding in Plain Sight Medical Devices is now the dominant engine, generating $5.54 billion in Q1 2026, up 13.2%. Inside that segment, the FreeStyle Libre continuous glucose monitor franchise cleared $2.08 billion in the quarter, growing 13.8%. CEO Robert Ford is explicit about the runway: “Our assessment of the number of people who should be on a CGM on a global basis is between 70 million and 80 million people. The market today is around 10 to 12 million people.”

Established Pharmaceuticals grew 13.2% and international sales rose 11.3%. Adjusted EPS came in at $1.15, the fourth consecutive beat, with full-year adjusted EPS guidance of $5.38 to $5.58. Abbott remains a compounder still compounding.

On March 23, 2026, Abbott closed its roughly $21 billion acquisition of Exact Sciences, launching a Cancer Diagnostics unit anchored by Cologuard and Cancerguard. Management expects approximately $3 billion of incremental sales in 2026. Ford framed the strategic logic: “About 50 million Americans are not up to date with CRC screening… Cologuard does really well here. Not only is it convenient at home, but its sensitivity at 95% is equivalent to colonoscopy.”

The Mispricing Shares closed most recently at $89.27, down 28.8% year to date and 32.1% over one year. The $116.54 analyst consensus target is below the 52-week high of $137.49, yet analysts overall still recommend buying shares. The forward P/E is 17.

_________________________________

What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)

__________________________________________

For investors weighing durable payers (our Dividend Kings research covers this cohort in depth), the disconnect between fundamentals and price action is notable.

Reframing the Legacy Drag Nutrition fell 6.0% to $2.02 billion, the piece of “old Abbott” the market fixates on. Ford has been clear that this is deliberate: “We did not reduce price uniformly; we kept it focused on products that… would demonstrate a positive volume response to reduced price.”

Nutrition volume recovery, FX, $0.20 per share of Exact Sciences dilution, China volume-based procurement, and continuous glucose monitoring competition from DexCom (NASDAQ:DXCM) are genuine. Polymarket traders currently place the probability of Q2 comparable sales growth falling within the 4% to 8% band at 44% to 45%. These are the concerns of a growth-plus-quality compounder.

This article is research commentary, not investment advice.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a Few Simple Questions. 

Get Matched with Vetted Advisors 

Choose Your  Fit 

Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)  

Contact [email protected] for any questions or corrections.

Abbott (ABT - Free Report) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +2.34%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.14 per share when it actually produced earnings of $1.15, delivering a surprise of +0.88%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $12.59 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $11.14 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Abbott shares have lost about 28.8% since the beginning of the year versus the S&P 500's gain of 10.6%.

What's Next for Abbott?While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.42 on $13.15 billion in revenues for the coming quarter and $5.48 on $50.42 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Perrigo (PRGO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.

This drug company is expected to post quarterly earnings of $0.39 per share in its upcoming report, which represents a year-over-year change of -31.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Perrigo's revenues are expected to be $1 billion, down 5% from the year-ago quarter.

Key Takeaways Abbott is seeing strong growth in EPD, led by emerging markets and biosimilar expansion. ABT is resetting its Nutrition business through innovation and pricing action to support long-term growth. Abbott faces risks from higher costs, macro uncertainty and foreign exchange impacts on reported results. Strong momentum in Abbott Laboratories' (ABT - Free Report) Nutrition business is expected to support growth in the coming quarters. The company is driving solid growth in emerging markets within the Established Pharmaceuticals Division (“EPD”) business. However, currency fluctuations and dull macro scenario may restrict Abbott’s growth potential.

In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 32.4% compared with the industry’s 27.5% decline. The S&P 500 composite has risen 23.3% in the same period. 

The leading at-home healthcare company has a market capitalization of $228.81 billion. Abbott beat on earnings in two of the trailing four quarters and matched in the other two, delivering an average surprise of 0.42%.

ABT’s TailwindsEPD Momentum Across Emerging Markets: Abbott’s EPD remains a steady contributor, supported by branded generics positions in faster-growing geographies. In the first quarter of 2026, EPD sales increased 13.2% on a reported basis and 9.0% on a comparable basis, with Key Emerging Markets up 9.4% on a comparable basis led by double-digit growth in several countries across Latin America and Asia Pacific. 

The company continues to focus on demand drivers such as chronic disease prevalence and expanding access to care, which support durable volume growth across therapy areas. It is also expanding its biosimilar portfolio, which should deepen its offering in key markets and help sustain above-market growth as the business scales.

Innovation-Led Reset in Nutrition: Abbott is working through a transition in Nutrition that is intended to restore a healthier balance between price and volume over time. In the first quarter of 2026, Nutrition sales declined 6.0% on a reported basis and 7.7% on a comparable basis, reflecting lower volumes and the impact of strategic pricing actions taken in the fourth quarter of 2025. Adult Nutrition remains an important franchise within the portfolio and a more consistent cadence of innovation, which should help it defend brand positions as category conditions normalize.

Image Source: Zacks Investment Research

What Ails ABT Stock?Macro and Cost Variability: Abbott continues to operate amid an uncertain macro backdrop that can influence input costs and demand patterns across categories. In the first quarter of 2026, selling, general and administrative expenses increased 22.2% year over year, partly reflecting acquisition-related items, and the company continues to incur incremental costs tied to European MDR and IVDR compliance. If pricing, mix or volumes weaken in areas such as Nutrition, Abbott may have less flexibility to offset these costs, which could weigh on profitability even with ongoing cost actions.

Foreign Exchange Can Swing Reported Results: Abbott’s large international revenue base makes reported growth sensitive to currency translation. Any reversal in currency trends would quickly reduce reported growth rates and complicate comparisons against expectations.

Abbott’s Estimate TrendThe Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $5.48 in the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at $50.42 billion, indicating a 13.7% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.

© Traimak_Ivan / iStock via Getty Images

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently. Abbott is down 22.99% year to date after a medtech correction. Pfizer sits flat, propped up by a 7.14% yield. Which discount is real, and which is a trap?

Devices Carry Abbott. Oncology Props Up Pfizer. Abbott’s Q1 revenue hit $11.16B, with Medical Devices up +13.2% to $5.54B. FreeStyle Libre alone did $2.08B, up 13.8%. Nutrition fell 6%, but the $21B Exact Sciences deal closed March 23, 2026, adding Cologuard and Cancerguard to a fast-growing diagnostics franchise. CEO Robert Ford called the quarter “aligned with our expectations”.

Pfizer posted $14.45B in revenue, with Oncology up 9% to $3.83B and Padcev surging 39%. Eliquis added 13%. COVID revenue continued eroding: Comirnaty fell 59%, Paxlovid dropped 62%. Albert Bourla framed 2026 as a “defining period”, leaning on oncology and obesity.

A Compounder Meets a Turnaround Abbott trades at a forward 17x earnings after the correction, with analysts targeting $116.72. Pfizer is cheaper on paper at a forward 8x, though its PEG sits at 2.815.

Lens Abbott Pfizer Core Bet Diabetes devices, cancer diagnostics Oncology, obesity, GLP-1 Dividend 54 straight years of hikes 7.14% yield, no buybacks in 2026 Key Vulnerability Exact Sciences dilution, FX Patent cliffs, tariff and MFN pricing risk Insider buying signals confidence. Abbott’s CFO Philip Boudreau bought 11,109 shares on April 23, 2026 near $92, and Director Daniel Starks added 10,000 shares.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Abbott Laboratories didn't make the cut. Grab the names FREE today.

The Next Test Is Pipeline Delivery Abbott must absorb the $0.20 Exact Sciences dilution while hitting the $5.38 to $5.58 full-year EPS range. Libre attach rates in Type 2 basal-insulin patients, backed by a 0.6% HbA1c reduction in the FreeDM2 trial, signal growth potential.

For Pfizer, Metsera obesity assets and roughly 20 pivotal 2026 studies must convert. Generic headwinds are real, and Most-Favored-Nation pricing plus tariff exposure make the $1.5B EPS guide fragile.

Why I Lean Toward Abbott at This Discount Pfizer’s 8x multiple and yield look tempting, but the setup screens as a value trap. COVID revenue is deflating, patent losses cost another $1.5B this year, and buybacks are paused. You are being paid to wait on a pipeline that has not proven itself.

Abbott, priced at a 16x forward multiple after the drawdown, feels cleaner. A 54-year dividend streak, medtech growth compounding at double digits, and insiders buying on the way down make it the better defensive play. If oncology and obesity readouts light up later this year, I will reconsider Pfizer. Until then, Abbott screens as the stronger risk-adjusted setup.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Abbott Laboratories didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

13.7.2026 14:09

Výsledková sezóna v USA se tento týden začíná rozbíhat. V centru pozornosti bude především finanční sektor, zejména výsledky velkých amerických bank, jako jsou JPMorgan Chase, Bank of America, Goldman Sachs, Wells Fargo, Citi či Morgan Stanley. Investoři budou sledovat také výsledky správce aktiv BlackRock. Mimo finance budou důležité také výsledky ze segmentu polovodičů, kde reportují ASML a TSMC. Pozornost investorů přitáhne rovněž Netflix, zatímco zdravotnický sektor zastoupí UnitedHealth Group, Johnson & Johnson, Abbott a Intuitive Surgical.

Přehled vybraných společností reportujících své výsledky v tomto týdnu (zdroj: síť X - Earnings Whispers)

Úterý (14. července) USA (před trhem): JPMorgan Chase, Bank of America, Goldman Sachs, Wells Fargo, Citi, Fastenal, Ericsson

Středa (15. července) USA (před trhem): Johnson & Johnson, ASML, Morgan Stanley, BlackRock, Progressive, The Bank of New York Mellon, PNC Financial Services, Elevance Health, Cintas, M&T Bank

USA (po trhu): United Airlines, J.B. Hunt Transport Services

Eurozóna (před trhem): ASML

Čtvrtek (16. července) USA (před trhem): UnitedHealth Group, General Electric, Abbott Laboratories, Prologis, U.S. Bancorp, Kinder Morgan, State Street, Citizens Financial Group

USA (po trhu): Netflix, Intuitive Surgical

Evropa (před trhem): ABB, Nordea Bank

Taiwan: TSMC

Pátek (17. července) USA (před trhem): The Travelers, Truist Financial, Fifth Third Bancorp, Regions Financial

Zdroj: Bloomberg, Earnings Whispers

Marek Krejčiřík
Fio banka, a.s.
Prohlášení

Demand for GLP-1 medicines is booming, as these drugs have proven highly effective at treating diabetes, obesity, and other conditions. Investors looking to capitalize on this may turn to the current leaders in the GLP-1 market: Eli Lilly (LLY +2.87%) and Novo Nordisk (NVO +0.69%). Both companies could be great picks to ride the GLP-1 tailwind over the medium term, but as competition grows in this niche, they may see declining market share and pricing power. There are other ways to profit from the GLP-1 boom that don't depend on picking whichever drugmaker will dominate it over the next five to 10 years. Let's consider two stocks that will cash in on this market no matter what: Becton, Dickinson and Company (BDX +0.49%) and Abbott Laboratories (ABT +0.22%).

Image source: Getty Images.

1. Becton, Dickinson Becton, Dickinson is a medical device manufacturer. The company has a large product portfolio, many of which are used daily by healthcare facilities. Becton, Dickinson is benefiting from the GLP-1 boom thanks to its status as a leading supplier of devices -- such as prefillable syringes -- that pharmaceutical companies use to deliver these medicines to patients. Becton, Dickinson has seen soaring demand for this segment of its business. The company is doubling down. At the beginning of the year, Becton, Dickinson announced it would invest $110 million to expand its production capacity for prefillable syringes to support the rising demand for GLP-1 drugs. The company is well-positioned to ride this wave through the end of the decade and beyond.

Today's Change

(

0.49

%) $

0.76

Current Price

$

156.30

In the meantime, there are other good reasons to buy the stock. Becton, Dickinson has a reliable business that generates consistent revenue and earnings, thanks in large part to the fact that more than 90% of its revenue is generated from recurring consumables. The healthcare giant has also gotten rid of some of its low-growth segments -- like its biosciences and diagnostic solutions unit -- which should eventually lead to stronger top-line growth. Lastly, Becton, Dickinson is a great dividend stock. The company has raised its payouts for 54 straight years, putting it above the threshold to be a Dividend King, which requires 50 or more consecutive annual payout increases. Becton, Dickinson is a great pick for long-term income seekers.

2. Abbott Laboratories Abbott Laboratories is a leader in the market for continuous glucose monitoring (CGM) devices that help diabetes patients track their blood sugar levels. Although some thought that the rise of GLP-1 medicines would lead to lower demand for CGM systems like Abbott's FreeStyle Libre, this hasn't happened. As Abbott Laboratories has argued, CGM adoption has continued to grow even as GLP-1s have become more popular.

That's likely partly because patients often use CGMs alongside GLP-1s. In fact, Abbott found in a study that FreeStyle Libre sensor adherence was higher for patients on GLP-1 medicines. Similarly, GLP-1 adherence was also higher among FreeStyle Libre users. So, if anything, these diabetes and weight loss drugs may actually drive higher usage of CGM devices, as physicians increasingly prescribe them together.

Today's Change

(

0.22

%) $

0.21

Current Price

$

95.84

That's good news for Abbott Laboratories, whose diabetes care segment has been its biggest growth driver for some time, thanks to the FreeStyle Libre. And as the company has pointed out, there is still significant white space in the CGM market. While the healthcare leader hasn't performed well lately, largely due to slowing growth in its nutrition and diagnostics segments, the opportunities in CGM may help it turn things around.

Further, Abbott Laboratories has expanded its diagnostics business through an acquisition that granted it access to the potentially lucrative cancer screening market. Lastly, Abbott is a Dividend King with 54 consecutive years of dividend increases. All these are good reasons why it is a strong buy-and-hold option.

When building a long-term, buy-and-hold portfolio in the healthcare sector, it is best to avoid biotech stocks, which can be more speculative, in favor of larger, more established healthcare companies with deep structural advantages.

Look for companies with wide economic moats, dependable dividends, reliable cash flows, and strong secular tailwinds from our aging population. Three of the best buy-and-hold healthcare stocks that fit this criteria perfectly are Johnson & Johnson (JNJ 2.19%), Abbott Laboratories (ABT 0.83%), and UnitedHealth Group (UNH 2.24%). Here's why I like each of these stocks.

Image source: Getty Images.

Johnson & Johnson's enormous R&D drives its success Johnson & Johnson is the ultimate set-it-and-forget-it healthcare giant. Since the 2023 spinoff of its consumer health division, now Kenvue, the company's remaining segments, innovative medicine and medtech, have improved the company's margins.

In the first quarter, Johnson & Johnson reported revenue of $24.1 billion, up 9.9%. Its adjusted earnings per share (EPS) of $2.70 topped analysts' expectations of $2.68. Johnson & Johnson upgraded its full-year forecast to say it expects between $99.7 billion and $100.7 billion in yearly sales, up 6.4% at the midpoint, and adjusted EPS of $11.45 to $11.65, up 7.1% at the midpoint.

Today's Change

(

-2.19

%) $

-5.77

Current Price

$

257.27

The company's huge research and development budget yields a steady pipeline of new therapeutics, helping insulate it against the regular patent cliffs that cripple smaller drugmakers. J&J spent more than $3.5 billion in the first quarter on R&D. The company's top launches this year are the plaque psoriasis treatment Icotyde and its integrated cardiac ablation platform, the Thermocool SmartTouch SF catheter.

The company has increased its dividend for 64 consecutive years, including a 3% boost this year, making it a Dividend King, one of the stocks that have increased their dividends for 50 or more years. Backed by a pristine balance sheet with $22.1 billion in cash and marketable securities, its dividend is arguably one of the safest among healthcare stocks.

Abbott Laboratories' diversity is its superpower Abbott is the gold standard for a diversified, multilayered bet on global healthcare demand. It operates across four major pillars: medical devices (including the continuous glucose monitoring system, Freestyle Libre), diagnostics, nutrition, and established pharmaceuticals.

Today's Change

(

-0.83

%) $

-0.80

Current Price

$

94.61

Abbott's geographic and operational diversification protects it against localized regulatory changes or single-product downturns. When one sector faces friction, another typically steps in to pick up the slack. For instance, surging demand for its cardiac and diabetes medical devices has consistently driven robust baseline growth. In the first quarter, while sales for its nutrition segment fell, sales for medical devices, diagnostics, and established pharmaceuticals all increased.

Abbott reported first-quarter sales of $11.2 billion, up 7.8% year over year, and adjusted EPS of $1.15, up 6% from the same period a year ago. It said it expects full-year revenue growth of 6.5% to 7.5% and full-year adjusted EPS of $5.38 to $5.58, up 6.4% at the midpoint, including $0.20 in dilution from its $21 billion acquisition of Exact Sciences. That deal is expected to bolster the company's sales of cancer screening and precision oncology diagnostics.

Abbott is a Dividend King. It has increased its dividend for 54 consecutive years, including a 6.8% raise effective this year, backed by efficient operational cash conversion that allows it to easily fund future organic growth and reward patient investors.

UnitedHealth Group's duality and size help it dominate Rather than betting on which manufacturer produces a drug or device, UnitedHealth lets you invest in the company that manages the system's capital flow. As the largest private health insurer in the U.S., it sits squarely at the center of the domestic economy.

Today's Change

(

-2.24

%) $

-9.52

Current Price

$

415.84

UnitedHealth Group's real strength lies in its dual-engine model. Beyond traditional health insurance, its Optum division manages data analytics, pharmacy care, and direct healthcare delivery. By serving its own insurance members through its own Optum clinics and pharmacies, it effectively captures profits on both ends of the healthcare delivery pipeline, a vertical integration advantage.

UnitedHealthcare Group reported first-quarter revenue of $111.7 billion, up 2% year over year, led by its UnitedHealthcare segment at $86.3 billion, up 2% from the first quarter of 2025. EPS was $6.90, up less than 1%, year over year. It said it expects full-year EPS of more than $17.35, up at least by 31%.

UnitedHealth Group generates huge, steady free cash flows, including $8.9 billion in the first quarter, or 1.4 times net income. While it has only raised its dividend for 17 consecutive years, its 2.1% yield is similar to those of Johnson & Johnson and Abbott, and it has boosted its dividend at a higher rate during the past decade.

Know what you're getting All three healthcare stocks provide low volatility and a high margin of safety. Their long records of dividend increases show how they have effectively managed high cash flows. Though their revenue growth isn't astronomical, all three companies benefit from built-in diversity, which serves them well, particularly in tough economic times.

The other reason to see these stocks as great buy-and-hold investments is that they consistently develop new revenue streams. Johnson & Johnson and Abbott invest heavily in R&D to develop new products, while UnitedHealth Group benefits from serving as both an insurer and a healthcare provider.

Choosing between established stability and high-tech growth often defines a portfolio. Whether you prefer the diversified reach of Abbott Laboratories (ABT +1.49%) or the specialized dominance of Intuitive Surgical (ISRG +1.17%), both offer compelling paths.

Abbott operates a broad healthcare empire spanning baby formula to heart valves, providing steady cash flows across market cycles. Intuitive Surgical focuses intensely on robotic-assisted surgery, benefiting from an ecosystem that generates significant recurring revenue. This comparison involves weighing broad diversification against narrow, high-margin specialization in the healthcare sector.

The case for Abbott LaboratoriesAbbott Laboratories operates across four primary segments, including medical devices, diagnostics, nutrition, and established pharmaceuticals. It sells these products globally to a diverse customer base of wholesalers, hospitals, clinics, and government agencies. In March 2026, the company completed its acquisition of Exact Sciences Corporation, a move designed to expand its presence in the cancer diagnostics market.

Financial results show the scale of these operations. In FY 2025, revenue reached nearly $44.3 billion, up roughly 5.7% from the previous year. Net income for the same period was close to $6.5 billion, while the company maintained a net margin of approximately 14.7%.

As an established player among medical device stocks, Abbott maintains a sturdy balance sheet. According to its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.3x, which measures total debt relative to shareholders’ equity. The current ratio, which gauges the ability to cover short-term obligations with short-term assets, stood at approximately 1.6x, and the company generated roughly $7.4 billion in free cash flow.

The case for Intuitive SurgicalIntuitive Surgical provides a robotic-assisted surgical ecosystem, primarily through its da Vinci and Ion platforms. The company generates revenue by selling these systems to hospitals and then providing the ongoing instruments, accessories, and services required for procedures. In early 2026, the company strengthened its international footprint by bringing several European distribution businesses in-house through strategic acquisitions.

Growth has remained robust for the robotic surgery pioneer. In FY 2025, revenue reached close to $10.1 billion, which was a significant increase of approximately 20.5% over the prior year. Net income for the period was roughly $2.9 billion, supported by a healthy net margin of nearly 28.4%.

Financial health remains a core strength for the company. As of its December 2025 balance sheet, the debt-to-equity ratio was 0.0x, indicating the company has virtually no debt relative to its equity. The current ratio was approximately 4.9x, and free cash flow reached nearly $2.5 billion. Note that stock-based compensation accounted for roughly 26.0% of operating cash flow, thereby inflating reported cash generation, since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparisonAbbott Laboratories faces several headwinds, including product liability and legal exposure related to its infant formula and spinal cord stimulators. The $20 billion in debt incurred to acquire Exact Sciences has also significantly increased its total indebtedness, reducing financial flexibility and increasing its sensitivity to interest rate changes. Furthermore, the company remains under intense regulatory scrutiny from the FDA regarding its manufacturing and marketing claims.

Intuitive Surgical must navigate complex global regulations and potential delays in regulatory reviews for its new products. The company is also vulnerable to cybersecurity threats that could compromise its connected surgical systems or patient data privacy. Additionally, the robotic-assisted surgery market is increasingly competitive, and consolidation among healthcare providers could lead to downward pressure on system pricing and profit margins.

Valuation comparisonAbbott Laboratories offers a significantly lower entry point based on sales and future earnings estimates compared to the premium valuation assigned to Intuitive Surgical.

MetricAbbott LaboratoriesIntuitive SurgicalSector BenchmarkForward P/E17.1x38.7x24.8xP/S ratio3.7x14.2xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Both of these companies appear to be good choices for a long-term investor’s portfolio. Both are leaders in their medical technology niches, and both have strong performance and growth potential. And although one may have slightly higher growth potential than the other, there are two other key differences driving investors’ choice.

Intuitive Surgical is the maker of the da Vinci robotic surgery platform. It’s installed in over 7,500 hospitals worldwide, and this technology has treated more than 20 million patients. It trades at a premium valuation relative to the broader medical technology and healthcare sectors, largely driven by its “razor-and-blades” model of recurring revenue from the sale of its instruments and accessories. It also benefits from high switching costs. However, it does not pay a dividend.

Abbott Laboratories is diversified. Its operations include pharmaceuticals, diagnostics, nutritional products, and medical devices. Its FreeStyle Libre continuous glucose monitoring system has driven growth in recent years, and its March 2026 acquisition of Exact Sciences represents another major expansion into cancer diagnosis. Abbott has a long track record of dividend increases, demonstrating it has the cash flow and stability to support them.

Investors seeking higher growth potential may prefer Intuitive Surgical. But for those looking for steady growth and dividend income, Abbott Laboratories is the stock I would choose.

Abbott (ABT - Free Report) closed the most recent trading day at $92.71, moving -1.5% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.18%. Meanwhile, the Dow gained 0.59%, and the Nasdaq, a tech-heavy index, added 2.07%.

Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 9.95% outpaced the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.

Analysts and investors alike will be keeping a close eye on the performance of Abbott in its upcoming earnings disclosure. The company's earnings report is set to go public on July 16, 2026. The company's earnings per share (EPS) are projected to be $1.28, reflecting a 1.59% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $12.53 billion, indicating a 12.43% growth compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $5.48 per share and revenue of $50.49 billion, which would represent changes of +6.41% and +13.9%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Abbott presently features a Zacks Rank of #4 (Sell).

Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 17.18 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.95.

Meanwhile, ABT's PEG ratio is currently 1.62. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 1.65 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 169, finds itself in the bottom 31% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.